213 related articles for article (PubMed ID: 26743240)
1. Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
Nagakura J; Yamakawa T; Taguri M; Tsuchiya H; Shigematsu E; Suzuki J; Morita S; Kadonosono K; Terauchi Y
Endocr J; 2016; 63(3):239-47. PubMed ID: 26743240
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
3. Once-daily liraglutide (1.2 mg) compared with twice-daily exenatide (10 μg) in the treatment of type 2 diabetes patients: An indirect treatment comparison meta-analysis.
Twigg SM; Daja MM; O'leary BA; Adena MA
J Diabetes; 2016 Nov; 8(6):866-876. PubMed ID: 26729046
[TBL] [Abstract][Full Text] [Related]
4. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
[TBL] [Abstract][Full Text] [Related]
5. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Lee WC; Conner C; Hammer M
Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
[TBL] [Abstract][Full Text] [Related]
6. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Lecube A; Bueno M; Suárez X
Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.
Gu S; Wang X; Qiao Q; Gao W; Wang J; Dong H
Diabetes Obes Metab; 2017 Dec; 19(12):1688-1697. PubMed ID: 28452095
[TBL] [Abstract][Full Text] [Related]
8. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
Buse JB; Nauck M; Forst T; Sheu WH; Shenouda SK; Heilmann CR; Hoogwerf BJ; Gao A; Boardman MK; Fineman M; Porter L; Schernthaner G
Lancet; 2013 Jan; 381(9861):117-24. PubMed ID: 23141817
[TBL] [Abstract][Full Text] [Related]
9. A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes.
Alshali KZ; Karawagh AM
Saudi Med J; 2016 Aug; 37(8):834-42. PubMed ID: 27464858
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
[TBL] [Abstract][Full Text] [Related]
14. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
15. Exenatide: new drug. Type 2 diabetes for some overweight patients.
Prescrire Int; 2007 Dec; 16(92):228-31. PubMed ID: 18087791
[TBL] [Abstract][Full Text] [Related]
16. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132
[TBL] [Abstract][Full Text] [Related]
17. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
Schernthaner G; Rosas-Guzmán J; Dotta F; Guerci B; Simó R; Festa A; Kiljański J; Zhou M; Gallwitz B
Diabetes Obes Metab; 2015 Jul; 17(7):689-98. PubMed ID: 25846577
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Kapitza C; Forst T; Coester HV; Poitiers F; Ruus P; Hincelin-Méry A
Diabetes Obes Metab; 2013 Jul; 15(7):642-9. PubMed ID: 23368510
[TBL] [Abstract][Full Text] [Related]
19. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
Buse JB; Sesti G; Schmidt WE; Montanya E; Chang CT; Xu Y; Blonde L; Rosenstock J;
Diabetes Care; 2010 Jun; 33(6):1300-3. PubMed ID: 20332351
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
